类风湿性关节炎缓解后的维持治疗研究进展

中国临床药理学与治疗学 ›› 2014, Vol. 19 ›› Issue (1): 116-120.

• 综述与讲座 • 上一篇

类风湿性关节炎缓解后的维持治疗研究进展

李小心¹, 徐亮²

¹皖南医学院内科学研究生2011级,芜湖 241001,安徽;
²皖南医学院附属弋矶山医院风湿科, 芜湖 241001,安徽

收稿日期:2013-03-16 修回日期:2013-10-30 出版日期:2014-01-27 发布日期:2014-02-12
通讯作者: 徐亮,男, 硕士, 主任医师、副教授,硕士生导师,研究方向:风湿免疫病学。Tel: 13956174906 E-mail: xuliang_57@sohu.com
作者简介:李小心,女,硕士研究生在读,研究方向:风湿免疫病学。Tel: 15155337955 E-mail: wyfsmyk@163.com

Development of maintenance treatment about rheumatoid arthritis in remission

LI Xiao-xin¹, XU Liang²

¹Grade 2011,Internal Medicine Graduate of Wannan Medical College, Wuhu 241001, Anhui, China;
²Department of Rheumatism, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China

Received:2013-03-16 Revised:2013-10-30 Online:2014-01-27 Published:2014-02-12

摘要/Abstract

摘要： 类风湿性关节炎(RA)是一种以关节的炎症损害为主要特点的复杂、多系统自身免疫性疾病。关于RA缓解期的药物使用一直是长期以来困扰风湿病学界的难点和热点。近年随着改变病情抗风湿药的日益成熟、生物制剂的快速发展,使RA的维持治疗手段和药物选择更具灵活性, 疗效、预后和药物不良事件控制较以往均有新的突破。本文就缓解后治疗的最新研究作一综述。

关键词: 类风湿性关节炎, 缓解期, 治疗

Abstract: Rheumatoid arthritis (RA) is a kind of complex and multi-system autoimmune disease with the main characteristics of the inflammation in joints .About the drug use of RA in remission is always a difficult and hot problem in rheumatology academia for a long time. In recent years, with the maturity of DMARDs and the rapid development of biological agents, the maintenance treatment and drug selection in RA is more flexible. New breakthrougs about curative effect, prognosis and the control of adverse events have been made in the past few years. Now the maintenance treatment of rheumatoid arthritis in remission was reviewed.

Key words: Rheumatoid arthritis, Remission, Treatment

中图分类号:

R392

李小心, 徐亮. 类风湿性关节炎缓解后的维持治疗研究进展[J]. 中国临床药理学与治疗学, 2014, 19(1): 116-120.

LI Xiao-xin, XU Liang. Development of maintenance treatment about rheumatoid arthritis in remission[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(1): 116-120.

参考文献

[1] Ruderman EM,Nola KM, Ferrell S,et al. Incorporating the treat-to-target concept in rheumatoid arthritis[J].Manag Care Pharm,2012 ,18(9):1-18.
[2] Pinals RS, Baum J,Bland J,et al.Preliminary criteria for clinical remission in rheumatoid arthritis[J].Bull Rheum Dis,1982,32(1):7-10.
[3] Felson DT, Smolen JS,Wells G,et al.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials[J].Arthritis Rheum,2011 ,63(3):573-586.
[4] Ranganath VK,KhannaD,PaulusHE,et al. ACR remission criteria and response criteria[J].Clin Exp Rheumato,2006,24(43):S14-S21.
[5] Silva LK, Ortiz AM, Patiño E,et al.Influence of the structure of mood in the assessment of rheumatoid arthritis through the visual analog scale for pain,HAQ and DAS28[J].Reumatol Clin,2012,8(6):328-333.
[6] Mãkinen H,Hannonen P, Sokka T.Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinicaltrials for the rate of remission[J].Clin Exp Rheumatol,2006,24(6):22-28.
[7] Smolen JS,Breedveld FC, Schiff MH,et al.A simplified disease activity index for rheumatoid arthritis for use in clinical practice[J].Rheumatology (Oxford),2003,42(2):244-257.
[8] Rotar Z,Praprotnik S,Tomšic M.Clinical contrasts with the American College of Rheumatology/European League Against Rheumatism provisional definitions of remission in rheumatoid arthritis for clinical trials:Comment on the article by Felson et al[J].Arthritis Rheum,2011 ,63(11):3642-3643.
[9] Smolen JS,Aletaha D,Bijilsma JWJ,et al.Treating rheumatoid arthritis to target: recommendations of an international task force[J].Ann Rheum Dis,2010,69 :631-637.
[10] Foltz V, Gandjbakhch F,Fautrel B,et al.Management of patients with rheumatoid arthritis in remission[J].Rev Prat,2012 ,62(8):1107-1112.
[11] Wessels JA,Vries-Bouwstra JK, Heijmans BT,et al.Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzyme[J].Arthritis Rheum,2006 ,54(4):1087-1095.
[12] Aletaha　D,Stamm　T,Kapral T,et al.Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study[J].Ann Rheum Dis,2003,62(10):944-951.
[13] Dervieux T,Zablocki R,Kremer J, et al.Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis[J].Rheumatology (Oxford),2010 ,49(12):2337-2345.
[14] Baggott JE, Morgan SL.Folic acid supplements are good (not bad) for rheumatoid arthritis patients treated with low-dose methotrexate[J].Am J Clin Nutr,2008 ,88(2):479-480.
[15] Prabhu P,Shetty R, Koland M, et al.Investigation of nano lipid vesicles of methotrexate for anti-rheumatoid activity[J].Int J Nanomedicine,2012,7:177-186.
[16] Emery P,Breedveld FC,Lemmel EM,et al.A comparison of the ef-i cacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis[J].Rheumatology,2000,39(6): 655-665.
[17] Wiacek R,Kolossa K,Jankowski T,et al.The efficacy and safety of leflunomide in patients with active rheumatoid arthritis[J].Adv Clin Exp Med,2012 ,21(3):337-342.
[18] McLaren ZL,Dawson JK.Comment on: Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid　arthritis[J].Rheumatology (Oxford), 2010,49(8):1606.
[19] Gabelle　A,Antoine JC,Hillaire　BD,et al.Leflunomide related severe　axonalneuropathy [J]. RevNeuro, 2005,161(11): 1106-1109.
[20] Lie E,Uhlig T,Heijde D,et al.Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA[J]. Rheumatology (Oxford),2012,51(4).670-678.
[21] Guin A, Chatterjee AM,Chakraborty S,et al.Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in　early rheumatoid arthritis:1-year follow-up study[J].Semin Arthritis Rheum,2013,12(13):48-54.
[22] Hara M,Abe T,Sugawara S,et al.Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study[J].Mod Rheumatol,2007,17(1):1-9.
[23] Furukawa K,Ohtani T, Furukawa F,et al.Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis[J].Mod Rheumatol,2007,17(6):492-495.
[24] Nakayama S,Yokote T,Kobayashi K,et al.Megaloblastic anemia associated with salazosulfapyridine treatment for rheumatoid arthritis[J].Rinsho Ketsueki, 2008,49(12):1609-1613.
[25] Kim WU,Yoo SA,Min SY,et al.Hydroxychloroquine potentiates Fas-mediated apoptosis of rheumatoid synoviocytes[J].Clin Exp Immunol, 2006,144(3):503-511.
[26] Saadat F,Cuzzocrea S,Di Paola R,et al.Effect of pyrimethamine in experimental rheumatoid arthritis[J]. Med Sci Monit,2005,11(8) :29.
[27] Rao AN,Shetty BV, Vasudevan DM,et al.Positive influence of Methotrexate-Hydroxychloroquine combination onthe expression of GM-CSF receptor onneutrophils of synovial fluid in rheumatoid arthritis[J].Indian J Clin Biochem,2006,21(2):49-52.
[28] Kavanaugh A,Fleischmann RM,Emery P,et al.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study[J].Ann Rheum Dis,2013,72(1):64-71.
[29] Mukai Y,Nakamura T,Yoshikawa M,et al.Solution of the structure of the TNF-TNFR2 complex[J].Sci Signal,2010,3(148):ra83.
[30] Horton S,Maya H Buch,Paul emery,et al.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations[J].Drug Healthc Patient Saf,2010,2:101-119.
[31] Shale M,Scow C,Cofin C,et al.Review article:chronic viral infeetion in the antitumor necrosis factor therapy era in inflammatory bowel disease[J].Aliment Pharmacol Therap,2010,31(1):20-34.
[32] Bongartz T,Sutton AJ,Sweeting MJ,et al.Anti-TNF antibody therapy in rheumatoid arthritis andthe riskof serious infections and malignancies: systematicreview and meta-analysis of rare harmful effects in randomized controlled trials[J].JAMA,2006,295:2275-2285.
[33] Setoguchi S, Solomon DH,Weinblatt ME,et al.Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis[J].Arthritis Rheum, 2006,54(9):2757-2764.

类风湿性关节炎缓解后的维持治疗研究进展

Development of maintenance treatment about rheumatoid arthritis in remission

PDF (PC)

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	张胡云龙, 朱秀之, 金希, 邵志敏. 腔面型乳腺癌内分泌治疗耐药的机制与治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 854-865.
[3]	付晓玉, 孔德光, 李娟娟. 三阳性乳腺癌的治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 866-875.
[4]	罗师萍, 张捷, 俞育帅, 宋传贵. HER2阳性乳腺癌的靶向治疗进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 876-886.
[5]	向奕玫, 张宁宁, 黄雨昕, 曾晓华. HER2阳性乳腺癌疗效相关生物标志物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 887-897.
[6]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[7]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[8]	李青华, 赵艳, 赵海港, 高朋飞, 徐炳欣. ABCB1 G2677T 基因多态性检测在缺血性脑卒中患者应用阿托伐他汀降脂治疗中的价值[J]. 中国临床药理学与治疗学, 2023, 28(6): 633-640.
[9]	王娟, 刘维英, 叶育才, 付文丽, 张莎, 李乐萍. 去甲肾上腺素再摄取抑制剂联合抗毒蕈碱剂治疗阻塞性睡眠呼吸暂停的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 714-720.
[10]	陈满新, 张丙雨, 戴敏. 冠状动脉内靶向应用重组人尿激酶原联合经皮冠状动脉成形术治疗高负荷血栓急性心肌梗死临床疗效[J]. 中国临床药理学与治疗学, 2023, 28(5): 544-549.
[11]	张莉, 蔺兴遥, 尚芸, 王强. 冻伤的病理机制及治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 347-354.
[12]	王铁烽, 苏洁, 王伟东, 夏荣双, 李思凡, 朱文瑞, 楼招欢. 三叶青调节Th17/Treg平衡抗类风湿性关节炎的作用及机制研究[J]. 中国临床药理学与治疗学, 2023, 28(2): 138-146.
[13]	俞亚红, 宋昱. 左心室辅助装置植入患者的药物治疗[J]. 中国临床药理学与治疗学, 2023, 28(2): 198-204.
[14]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[15]	吴莉莉, 梁至, 黄思咏, 王妍. 肾功能亢进对感染性心内膜炎患者万古霉素药动学的影响及有效性与安全性研究[J]. 中国临床药理学与治疗学, 2023, 28(10): 1139-1145.